IL160825A0 - Transdermal administration of an enalapril ester - Google Patents

Transdermal administration of an enalapril ester

Info

Publication number
IL160825A0
IL160825A0 IL16082502A IL16082502A IL160825A0 IL 160825 A0 IL160825 A0 IL 160825A0 IL 16082502 A IL16082502 A IL 16082502A IL 16082502 A IL16082502 A IL 16082502A IL 160825 A0 IL160825 A0 IL 160825A0
Authority
IL
Israel
Prior art keywords
enalapril
ester
transdermal administration
transdermal
administration
Prior art date
Application number
IL16082502A
Other languages
English (en)
Original Assignee
Noven Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noven Pharma filed Critical Noven Pharma
Priority claimed from PCT/US2002/025981 external-priority patent/WO2003022270A1/en
Publication of IL160825A0 publication Critical patent/IL160825A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16082502A 2001-09-13 2002-09-13 Transdermal administration of an enalapril ester IL160825A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31863201P 2001-09-13 2001-09-13
US10/014,785 US6805878B2 (en) 2001-09-13 2001-12-14 Transdermal administration of ACE inhibitors
PCT/US2002/025981 WO2003022270A1 (en) 2001-09-13 2002-09-13 Transdermal administration of an enalapril ester

Publications (1)

Publication Number Publication Date
IL160825A0 true IL160825A0 (en) 2004-08-31

Family

ID=26686515

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16082502A IL160825A0 (en) 2001-09-13 2002-09-13 Transdermal administration of an enalapril ester

Country Status (8)

Country Link
US (2) US6805878B2 (ja)
JP (1) JP2005502689A (ja)
KR (1) KR20040044907A (ja)
BR (1) BR0212506A (ja)
CA (1) CA2460190A1 (ja)
IL (1) IL160825A0 (ja)
RU (1) RU2004111534A (ja)
TW (1) TWI309982B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526973T1 (de) * 2001-06-18 2011-10-15 Noven Pharma Verbesserte arzneimittelabgabe in transdermalen systemen
AU2005209045B2 (en) * 2004-01-30 2011-02-24 Ace Aps Use of ACE inhibitors and/or angiotensin II receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing
US8765678B2 (en) * 2005-07-27 2014-07-01 Mor Research Applications Ltd. Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology
MX362949B (es) * 2008-12-04 2019-02-27 Yu Chongxi Composiciones de alta penetracion y sus aplicaciones.
EP2537534B1 (en) 2011-06-22 2014-12-17 Hexal AG Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4213978A (en) 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4847250A (en) 1985-11-29 1989-07-11 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US5925372A (en) 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5405486A (en) 1988-03-04 1995-04-11 Noven Pharmaceuticals, Inc. Apparatus for forming a transdermal drug device
US5073539A (en) 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
FR2664815B1 (fr) 1990-07-23 1994-11-04 Adir Systeme matriciel autoadhesif pour la liberation prolongee du piribedil par voie transcutanee.
EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
US5622944A (en) 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
EP0581587A3 (en) 1992-07-31 1995-05-17 Tanabe Seiyaku Co Base material for transdermal administration.
DE69433994T2 (de) 1993-01-19 2005-09-22 Endorecherche Inc., Ste-Foy Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE19512181C2 (de) 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
BR0010166A (pt) 1999-04-30 2002-06-04 Millennium Pharm Inc Composto modulador de ace-2, composto inibidor de ace-2, métodos para o tratamento de um estado associado a ace-2 em um paciente e para inibir a hidrólise de um peptìdeo de marcação de ace-2, e, composição farmacêutica
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
DE10033855A1 (de) 2000-07-12 2002-01-31 Hexal Ag Matrixkontrolliertes transdermales System mit Sulfonsäuresalz eines ACE-Hemmers

Also Published As

Publication number Publication date
JP2005502689A (ja) 2005-01-27
US20050100589A1 (en) 2005-05-12
US6805878B2 (en) 2004-10-19
BR0212506A (pt) 2004-08-24
TWI309982B (en) 2009-05-21
RU2004111534A (ru) 2005-03-10
KR20040044907A (ko) 2004-05-31
US20030064933A1 (en) 2003-04-03
CA2460190A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
IL157822A (en) Transdermal patch for fentanyl or analogue
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
PT2527342E (pt) Derivados do éster cíclico uk-2a úteis para a prevenção ou tratamento de doenças fúngicas
AU2002322719A1 (en) Delivery of therapeutic capable agents
AU2002252415A1 (en) Treatment of lipid pool
HUP0302926A3 (en) Composition for the transdermal delivery of fentanyl
AU1585601A (en) Transdermal administration of huperzine
HUP0301164A3 (en) Method of administering bisphosphonates
AU2002328328A1 (en) Transdermal therapeutic system with fentanyl or related substances
HUP0401512A3 (en) Transdermal therapeutic system (tts) with fentanyl as active ingredient
AU2002210463A1 (en) Transdermal therapeutic system
GB0119012D0 (en) Transdermal delivery of drugs
GB0202900D0 (en) Novel formulations of drugs
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
IL160825A0 (en) Transdermal administration of an enalapril ester
EP1670755A4 (en) PYROVALERON ANALOGUE AND ITS THERAPEUTIC APPLICATIONS
SI1296689T1 (sl) Nacin dajanja pacientu bisfosfonatov
EP1284730A4 (en) MILD MEDICINES WITH ARALKYL ESTER
HUP0104968D0 (en) Transdermal pharmaceutical composition containing aspirine for the treatment of sclerosis
GB9817348D0 (en) Pharmaceutical use of esters
AU6106801A (en) Trans-clitoral administration of therapy
AU5725000A (en) Pseudomycin amide and ester analogs
AU2002366591A1 (en) Method of administering calcium citrate